Literature DB >> 28461147

Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis.

Roland Diel1, Felix Ringshausen2, Elvira Richter3, Lutz Welker4, Jochen Schmitz4, Albert Nienhaus5.   

Abstract

BACKGROUND: Pulmonary disease caused by nontuberculous mycobacteria (NTM) is steadily increasing worldwide.
METHODS: A systematic review of non-Mycobacterium avium complex studies published prior to October 2016 was conducted with respect to microbiological and clinical outcomes of current treatment regimens.
RESULTS: We retrieved 352 citations, which yielded 24 studies eligible for evaluation. Sixteen studies were retrospective chart reviews, three studies were prospective, and only five studies were randomized. The weighted average proportion of sputum culture conversion (SCC) after subtracting posttreatment relapses for patients with M abscessus was 41.2% (95% CI, 28.6%-54.5%) but was 69.8% (95% CI, 41.0%-91.9%) with subspecies M massiliense in macrolide-containing regimens, 80.2% (95% CI, 58.4%-95.2%) in patients with M kansasii, 32.0% (95% CI, 16.5%-49.8%) for M xenopi (MX) and 54.4% (95% CI, 34.7%-73.4%) for M malmoense. SCCs in the total of 55 patients who underwent lung resection and had MX or M abscessus was high at 75.9%. The risk of bias was low in four of five randomized studies. However, heterogeneous use of outcome parameters (eight definitions of "relapse," eight of "treatment success," and four of "cure") hampered comparison of nonrandomized studies as well as producing possible bias by a posteriori exclusion (13.3%) and uncompleted treatment of participants (25.3%).
CONCLUSIONS: As a sustained microbiological response without surgery is unsatisfactory in treating M abscessus, MX, and M malmoense, functional and quality of life aspects should be given more emphasis in the individual evaluation of treatment outcome. Further, properly planned studies with sufficient power are needed, as are new drugs or better-tolerated application of current antibiotics, or both.
Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  meta-analysis; nontuberculous mycobacteria; systematic review; treatment outcome

Mesh:

Year:  2017        PMID: 28461147     DOI: 10.1016/j.chest.2017.04.166

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  43 in total

1.  β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.

Authors:  Elizabeth Story-Roller; Christos Galanis; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Clofazimine for the Treatment of Mycobacterium kansasii.

Authors:  Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

5.  Mycobacterium abscessus Clearance by Neutrophils Is Independent of Autophagy.

Authors:  Kerstin Pohl; Xue A Grimm; Silvia M Caceres; Katie R Poch; Noel Rysavy; Milene Saavedra; Jerry A Nick; Kenneth C Malcolm
Journal:  Infect Immun       Date:  2020-07-21       Impact factor: 3.441

6.  Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Authors:  Moti Chapagain; Tawanda Gumbo; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.

Authors:  Hee Jae Huh; Su-Young Kim; Hyang Jin Shim; Dae Hun Kim; In Young Yoo; On-Kyun Kang; Chang-Seok Ki; So Youn Shin; Byung Woo Jhun; Sung Jae Shin; Charles L Daley; Won-Jung Koh; Nam Yong Lee
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

8.  Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.

Authors:  Byung Woo Jhun; Bumhee Yang; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; O Jung Kwon; Jungmin Ahn; Il Joon Moon; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Su-Young Kim; Byung Woo Jhun; Seong Mi Moon; Sun Hye Shin; Kyeongman Jeon; O Jung Kwon; In Young Yoo; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Gee Young Suh; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

10.  Pulmonary Cavity From Mycobacterium malmoense in an HIV-Infected Patient: Complicated by Bronchopleural Fistula.

Authors:  Eric Abston; Harrison Farber
Journal:  Open Forum Infect Dis       Date:  2018-01-24       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.